STOCK TITAN
  1. Home
  2. News
  3. STAA

Staar Surgical Co. - STAA STOCK NEWS

Welcome to our dedicated news page for Staar Surgical Co. (Ticker: STAA), a resource for investors and traders seeking the latest updates and insights on Staar Surgical Co..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Staar Surgical Co.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Staar Surgical Co.'s position in the market.

News
STAAR Surgical Announces Preliminary Net Sales for First Quarter 2024
Rhea-AI Summary
STAAR Surgical (STAA) reported total net sales exceeding $77 million for the first quarter of 2024, with record U.S. ICL sales of $5 million. The company anticipates fiscal 2024 net sales to be at the higher end of the previously announced range of $335 million to $340 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.48%
Tags
earnings
-
News
STAAR Surgical Celebrates Three Million Lens Milestone at ASCRS Meeting, Unveils New EVO ICL Data and Latest Innovation for 2024
Rhea-AI Summary
STAAR Surgical Company (STAA) showcases EVO ICL at ASCRS with 44 posters and presentations, hitting a commercial milestone of three million lenses sold. The company focuses on clinical education, featuring Will Levis from Tennessee Titans. New ordering platform, Stella™, to launch in Spring/Summer '24.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.31%
Tags
none
-
News
STAAR Surgical Celebrates Three Million Implantable Collamer® Lenses
Rhea-AI Summary
STAAR Surgical Company announces the sale of over three million EVO ICL lenses globally, marking a significant milestone in vision correction. The EVO ICL lens offers a minimally invasive solution for myopia, astigmatism, and presbyopia, with clear advantages in patient outcomes and satisfaction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.83%
Tags
none
News
STAAR Surgical Adds Arthur Butcher and Wei Jiang to Board of Directors
Rhea-AI Summary
STAAR Surgical Company (STAA) appoints Arthur Butcher and Wei Jiang, seasoned healthcare executives, to its Board of Directors, bringing extensive experience in the medical device and pharmaceutical industries, particularly in the APAC region. The company also announces the departure of director K. Peony Yu. With these changes, the STAAR Surgical Board now consists of eight directors, seven of whom are independent non-employee directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.94%
Tags
management
-
News
STAAR Surgical to Participate in Two Upcoming Investor Conferences
Rhea-AI Summary
STAAR Surgical Company (STAA) to participate in investor meetings at Oppenheimer Healthcare MedTech & Services Conference and Sidoti Small Cap Conference. Also, meetings planned in China from March 18-20.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.67%
Tags
conferences
-
News
STAAR Surgical Reports Fourth Quarter and Fiscal Year 2023 Results
Rhea-AI Summary
STAAR Surgical Company (STAA) reports double-digit sales growth and profitability in Q4 2023. Net sales up 19% to $76.3 million, ICL sales up 22% to $74.6 million. Fiscal year 2023 net sales increased by 13% to $322.4 million. Gross margin remains strong. Net income for the year at $21.3 million. Earnings per share at $0.43.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.93%
Tags
earnings
News
STAAR Surgical to Report Fourth Quarter Results on February 26, 2024
Rhea-AI Summary
STAAR Surgical Company (NASDAQ: STAA) will release financial results for the fourth quarter ending December 29, 2023, on February 26, 2024. The company will host a conference call to discuss its financial results and operational progress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
News
STAAR Surgical Announces Strategic Agreement in U.S. with SharpeVision
Rhea-AI Summary
STAAR Surgical Company (NASDAQ: STAA) has announced a strategic agreement with SharpeVision to provide EVO ICL lenses as the first choice for patients seeking visual freedom from contact lenses and glasses. The collaboration includes marketing and education activities to increase awareness and availability of the lenses to all qualified patients in SharpeVision clinics. The initial stage of the collaboration includes a target purchase amount of 1,000 ICL units annually, which represents approximately 25% of the group’s refractive procedure volume. The EVO ICL lens can permanently correct vision without removing corneal tissue and is removable by a doctor for added peace of mind. The lens aims to eliminate the hassles of glasses and contact lenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.69%
Tags
none
-
News
STAAR Surgical Announces Preliminary Results for Fourth Quarter and Fiscal 2023
Rhea-AI Summary
STAAR Surgical Company (NASDAQ: STAA) reported a 19% increase in net sales for the fourth quarter and a 13% increase for fiscal 2023. The company also announced a sales outlook of $335 million to $340 million for fiscal 2024. Operating margin is expected to be approximately 5% for both the fourth quarter and fiscal 2023. Global ICL sales increased 22% in the fourth quarter and 18% for fiscal 2023, with a positive market share gain and continued profitability. The company's cash, cash equivalents, and investments available for sale also increased to approximately $230 million as of December 29, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.52%
Tags
earnings
News
Lilian Zhou Appointed to STAAR Surgical Board of Directors
Rhea-AI Summary
STAAR Surgical Company (NASDAQ: STAA) appoints Lilian Zhou, an accomplished investment portfolio manager, to its Board of Directors. Ms. Zhou brings over two decades of capital markets and investment experience to STAAR, having worked at highly regarded Wall Street investment institutions and founded her own firm. The company also announced the departure of Gil Kliman, M.D., from the board to focus on other commitments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.61%
Tags
management
Stock STAA logo
Staar Surgical Co.

Nasdaq:STAA

STAA Rankings

#1767 Ranked by Market Cap
#4537 Ranked by Stock Gains
N/A Ranked by Dividends

STAA Stock Data

2.43B
37.60M
0.78%
107.7%
10.79%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Lake Forest

About STAA

staar surgical company (nasdaq: staa), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye has been dedicated solely to ophthalmic surgery for over 30 years. the company offers the evo visian implantable collamer® lenses (icls) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and hyperopic icl, which treats far-sightedness. these lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. all of these lenses are foldable, which permits the surgeon to insert them through a small incision. staar's lens used in refractive surgery is called an implantable collamer lens or "icl"​. nearly 600,000 visian icls have been implanted to date. it also provides minimally invasive intraocular lenses (iols), including foldable iols for use in minimally invasive cataract surgical procedures; aspheric iols that produce a clearer image than trad